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Corticotropin-releasing factor (CRF) is a key player in the regulation of the hypothalamic-
pituitary-adrenal axis. CRF neurons cannot be distinguished morphologically from other 
neuroendocrine neurons in the paraventricular nucleus of the hypothalamus (PVH) without 
immunostaining.  Thus a knock-in mouse (CRF-Venus) was generated by Itoi and colleagues 
by inserting Venus (enhanced yellow fluorescent protein) gene at the translation initiation site 
of the CRF gene by homologous recombination, and yet, its expression is driven by the CRF 
promoter and responds to changes in milieu interieur. In the present study, I examined the 
distribution of Venus-expressing neurons all through the mouse brain including the PVH and 
compared it with that of CRF expression. In the CRF-Venus, Venus-expressing neurons were 
distributed in brain regions harboring CRF neurons, including the paraventricular nucleus of 
the hypothalamus (PVH). In the PVH, Venus was expressed selectively in CRF neurons, but a 
considerable proportion of Venus neurons did not express CRF in a physiological 
glucocorticoid (GC) state. Following GC deprivation, Venus expression and CRF expression 
were enhanced in the PVH, and most Venus neurons became expressing of CRF. Conversely, 
expression of Venus and CRF was suppressed by excess GC. In PVH-Venus neurons, 
expression of copeptin, a peptide coded within the vasopressin gene, was induced by 
deprivation of GC, which was suppressed by GC administration. Thus, Venus neurons 
recapitulated partly the GC-dependent responses of PVH-CRF neurons. This mouse line 
carried PGK-neo sequence flanking with frt sequence as a positive selection marker for 
homologous recombination. To examine whether the PGK promoter may have influenced the 
Venus expression in CRF neurons, another mouse line, CRF-Venusneo was generated by 
breeding CRF-Venus with Actb-Flp Knock-in mouse, and thereby the PGK-neo sequence was 
deleted from the genomic sequence of the CRF-Venus mouse. In the CRF-Venusneo, Venus 
was expressed more prominently throughout the brain, and in the PVH, it was expressed 
more constitutively and most of the Venus-expressing neurons co-localized with CRF in a 
physiological GC state. With an identical strategy that was used for generating the CRF-
Venus, CRF-iCre knock-in mouse was generated. By crossing CRF-iCre with a CAG-CAT-





mouse was obtained. EGFP was expressed more constitutively in PVH-CRF neurons of the 
EGFP/CRF-iCre mouse. The mouse models, presented in the present study, will be of great 
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The hypothalamus is the integrating center for stress responses [1] and the major 
neuroendocrine response to stress is via activation of the hypothalamic pituitary adrenal 
(HPA) axis, consisting of parvocellular neurons in the paraventricular nucleus of 
hypothalamus (PVH) and consequent release of the neuropeptides, corticotrophin releasing 
factor(CRF) and arginine vasopressin (AVP), which stimulate pituitary adrenocorticotropic 
hormone (ACTH) release. This leads to stimulation of glucocorticoid secretion by the adrenal 
cortex, which is essential for stress adaptation. Glucocorticoids (cortisol in humans and 
corticosterone in rats and mice) act upon specific receptors present in most peripheral tissues 
and in the brain, initiating metabolic and neuromodulatory changes necessary for coping with 
the challenge and CRF and AVP neurons convert stress signals to hormonal outputs [2].  
 
Corticotropin-releasing factor (CRF) is a 41 amino acid peptide that is synthesized in 
multiple brain regions. In the cortical mantle and basal telencephalon, CRF neurons are 
usually expressed in the olfactory tubercle, nucleus accumbens, lateral septum, and medial 
preoptic area, bed nucleus of stria terminalis and in the central nucleus of amygdala. In the 
cerebral cortex, CRF interneurons are contained in the second and third layers and project to 
layers I and IV. The highest density of CRF containing neurons is found in the prefrontal, 
insular and cingulate cortex. In addition with PVH, the CRF neurons also expressed other 
different parts of diencephalon such as lateral hypothalamic area, zona incerta, and also in the 
medial geniculate nucleus. In the midbrain and pons, CRF neurons are expressed in the 
periaqueductal gray, median raphe nucleus, peduncular pontine tegmental nucleus, 
laterodorsal tegmental nucleus, and in the lateral parabrachial nucleus. In the medulla, CRF 
neurons are known to exist in the inferior olive and nucleus of the solitary tract [3-6]. CRF 
neuron has been proposed to play roles in a variety of physiological functions including 
endocrine stress response [3] , feeding behavior [7], autonomic regulation [8, 9], emotional 
responses [10], and cerebellar plasticity [11].  
 
The CRF neurons are regulated by numerous neural inputs, including noradrenaline (NA) 
[12-14], glutamate [15], and γ-aminobutyric acid (GABA) [15]. The noradrenergic afferents 
make direct synaptic contacts with CRF neurons [16], but they may affect CRF neuronal 
activity indirectly via glutamatergic or GABAergic interneurons [15, 16]. CRF neurons 




present in the PVH, particularly after adrenalectomy, may also express AVP and these 
neurons are classified as parvocellular (from the Latin, ‘‘parvus’’– meaning small) because of 
their small size compared with the large size magnocellular neurons and they project to the 
external zone of the median eminence and release their product to the pituitary portal 
circulation in response to stress [17-19]. CRF neurons in this area co-express other peptides 
including AVP, enkephalins, cholecystokine and angiotensin II, and are intermingled with 
other neuroendocrine neurons such as oxytocin (OXT)-, thyrotropin-releasing hormone 
(TRH)-, and somatostatin (SRIF), galanin, growth hormone releasing hormone and tyrosine 
hydroxylase expressing dopaminergic neurons [20]. However, most AVP neurons present in 
the PVH and in the supraoptic nucleus are magnocellular, and these neurons project to the 
posterior pituitary through the internal zone of the median eminence [1, 19, 21]. 
Glucocorticoid (GC), secreted from the adrenals, is the major humoral factor that inhibits the 
activity of the CRF neurons in the parvocellular PVH and constitutes the negative-feedback 
loop of the HPA axis [22, 23]. 
 
CRF expression is markedly increased in the rat PVH after bilateral adrenalectomy, and this 
increase can be suppressed by glucocorticoids [1, 24]. The glucocorticoid suppression is 
specific for the PVH because CRF mRNA expression is unaffected or up-regulated in, for 
example, the central nucleus of the amygdala or the supraoptic nucleus. The molecular 
mechanisms for negative glucocorticoid regulation of CRF expression are not fully 
understood. Glucocorticoid receptors (GRs) are required, but their interactions with specific 
DNA-regulatory sequences and other transcription factors may be cell-type specific [1]. 
 
AVP itself is a weak ACTH secretagogue, but it potentiates the stimulatory effects of CRF on 
ACTH release from the corticotrophs. AVP in the parvocellular neurons of the PVH are also 
negatively regulated by glucocorticoids and it is up regulated with withdrawal of the negative 
feedback by adrenalectomy [25, 26]. 
 
Despite considerable efforts in previous studies, it has been hard to unravel the cellular 
physiological mechanisms for regulating CRF neurons since they cannot be distinguished 
morphologically from other neuroendocrine neurons, e.g., vasopressin (AVP)-, oxytocin 
(OXT)-, thyrotropin-releasing hormone (TRH)-, and somatostatin (SRIF)-producing neurons. 
On the other hand visualizing central sites of endogenous mouse CRF expression through 
immunohistochemistry has proved difficult without prior brain administration of compounds 




such as colchicine [5, 27, 28] that inhibit axonal transport and promote the somatic 
accumulation of neuropeptides but this approach makes physiological experiments unreliable. 
The efforts to develop an animal model that enables visualization of CRF neurons without 
staining have not been successful, even in mice generated by bacterial artificial chromosome 
(BAC) transgenic strategy [29]. Recently, Wamsteeker Cusulin and colleagues reported a 
method for visualizing CRF neurons by crossing a Crh-IRES-Cre knock-in mouse with a 
TdTomato reporter (Ai14) [28, 30].  
 
Itoi and colleagues generated two mouse lines to visualize CRF neurons by Venus (modified 
yellow fluorescent protein), and yet, the Venus expression is under the control of the CRF 
promoter and responds to the changes in milieu interieur. In the CRF-Venus mouse, the Venus 
gene was inserted to the CRF gene by homologous recombination so that CRF neurons could 
be visualized by Venus. A DNA fragment, which carried Venus sequence and pgk-1 promoter-
driven neomycin phosphotransferase gene (Neo) flanked by two Flp recognition target (frt) 
sites, was inserted into the translation initiation site of the exon 2 of CRF gene under the 
promoter of CRF. With an identical strategy, CRF-iCre knock-in mouse was generated by Itoi 
and colleagues. In the CRF-iCre, iCre sequence was inserted at the CRF genomic locus, and 
otherwise, all the genomic sequences were identical to those of the CRF-Venus mouse. 
Another mouse line, CRF-Venus∆neo was also generated; in the CRF-Venus∆neo, neomycin 
phosphotransferase gene (Neo) was deleted from the genomic sequence of the CRF-Venus 










 (Z/CRF-iCre) was obtained by crossing CRF-iCre with a lacZ (an E. coli -
galactosidase)-reporter (CAG-CAT-Z) mouse. In these reporter mice, either the EGFP or lacZ 
gene was driven by the CAG promoter. In addition, the chloramphenicol acetyltransferase 
(CAT) gene, flanked by the loxP sequence, was located between the CAG promoter and the 
lacZ gene.  
 
The main purpose of the study was immunohistochemical characterization of Venus/EGFP 
expression in the CRF neuron of different mouse lines. The second purpose of this study was 
to examine whether the Venus expression in the CRF-Venus mouse is dependent on the states 
of endogenous glucocorticoids (GC), corticosterone (B), by GC deprivation or administration 
of excess B. Since parvocellular AVP is responsive to GC levels, it was also examined 




whether the expression of copeptin, a peptide encoded within AVP gene, is GC-dependent in 
Venus neurons of CRF-Venus mouse.  
 
 
Therefore, the present research was undertaken with the following specific objectives: 
 
1. Distribution and comparison of Venus expression in the PVH between CRF-Venus and 
CRF-Venus∆neo mouse. 
2. Distribution of more constitutive EGFP expression in the PVH of EGFP/CRF-iCre 
mouse. 
3. Localization of Venus and EGFP-labeled neurons with vasopressin (AVP), oxytocin 
(OXT), somatostatin (SRIF) and thyrotropin-releasing hormone (TRH) in the CRF-
Venus and EGFP/CRF-iCre brain respectively. 
4. Distribution of Venus and EGFP-labeled neurons in the outside of PVH of all mouse 
line. 
5. Glucocorticoid dependent expression pattern of Venus neurons in the PVH of CRF-
Venus mouse.  
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Materials and methods 
2.1. Generation of CRF-Venus, CRF-Venus∆neo, CRF-iCre, Z/CRF-iCre, and 
EGFP/CRF-iCre mouse. 
 
Mice carrying Venus or iCre in the Crf genomic locus were produced by homologous 
recombination using the C57BL/6N ES cell line RENKA [31]. A targeting vector, constructed 
in accordance with the mouse genomic DNA databases, contained exon 1 and 2 of Crf gene 
with a 5.8 kb upstream- and a 4.2 kb downstream homologous genomic DNA fragment and 
the diphtheria toxin gene for negative selection (Figure 1). A DNA fragment, which carried 
Venus- or iCre sequence and pgk-1 promoter-driven neomycin phosphotransferase gene 
(Neo) flanked by two Flp recognition target (frt) sites, was inserted into the translation 
initiation site of the exon 2. Homologous recombination in the ES cells and chimeric mice 
production were carried out as described previously [31] . Homologous recombinants were 
identified by Southern blot analyses: Hind III-digested DNA fragments, hybridized with the 
5'-probe, were 15.2 kb, 8.7 kb, and 9.1 kb for wild-type (WT)-, targeted Crf-Venus-, and 
targeted Crf-iCre allele, respectively; Nhe I-digested DNA fragments, hybridized with the 3'-
probe, were 8.8 kb, 11.5 kb, and 11.8 kb for WT-, targeted Crf-Venus-, targeted Crf-iCre 
allele, respectively; Nde I-digested DNA, hybridized with Neo probe, were 11.7 kb and 12.0 
kb for targeted Crf-Venus- and targeted Crf-iCre allele, respectively. ES cell clones with the 
correct recombination were used to yield chimeric mice as described previously [32] . 
Chimeric mice were mated with C57BL/6N WT mice, and offspring were used for breeding 
and experiments. For all subsequent breeding, genotypes were determined by PCR analyses 
of digested mice tail samples. The following primers were used for PCR: forward, 5'-
GACCAATCTTACCTTTCTCC-3'; reverse, 5'-AGAAGTCGTGCTGCTTCATG-3' for Crf-
Venus allele, and forward, 5'-GACCAATCTTACCTTTCTCC-3'; reverse, 5'-
AGGTGGCATCCACAGGGAGG-3' for Crf-iCre allele. 
 
CRF-Venus heterozygous mice and CRF-iCre heterozygous mice were generated by breeding 
with wild-type C57BL/6N mice (CLEA, Tokyo, Japan). Crossing the CRF-iCre/wt with either 









 (EGFP/CRF-iCre) mouse. The iCre-mediated 
recombination was verified by X-gal staining in the Z/CRF-iCre and EGFP staining in the 
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EGFP/CRF-iCre (vide infra).  
 
For the generation of CRF-Venus∆neo heterozygous mice (Figure 1), firstly CRF-Venus 
heterozygous mice was crossed with Actb-Flp knock-in mice (Abe et al., unpublished) .In the 
obtained CRF-venus;Actb-Flp, Neo cassette was removed and they were used to generate 
CRF-Venusneo without Actb-Flp by crossing with wild type C57BL/6N mice.  
 
2.2. Animal housing and Colchicine infusion 
 
Mice were housed at constant temperature (23°C) and humidity (55%) with 12h/12h light-
dark cycle (lights on from 07:00-19:00) and allowed free access to drinking water and pellets. 
Male CRF-Venus mice were used for glucocorticoid dependent Venus expression study but 
sex did not consider for other distribution study. Mice were anesthetized deeply with chloral 
hydrate (400 mg/kg), and intracerebroventricularly (i.c.v) treated with colchicine (30 g 
dissolved in 2 l saline) by unilateral injection through a glass capillary placed into the lateral 
ventricle under stereotaxic control (coordinates from Bregma: anteroposterior, −0.2 mm; 
lateral, −0.9 mm; dorsoventral from dura, −2.0 mm). 
 
2.3. Surgery and stress less removal of corticosterone 
 
A group of CRF-Venus mice underwent bilateral adrenalectomy or sham-operation. Bilateral 
adrenalectomy (ADX) was performed via the dorsal route under chloral hydrate (400 mg/kg 
body weight) anesthesia. The surgical procedure of sham-operation was identical to that of 
ADX except that both adrenals were exposed but not removed. Dallman and Jacobson et al. 
model was employed for stress less removal of corticosterone (B) [35, 36] . For sham group, 
mice were given only drinking fluid (0.45% saline and 2.5% dextrose). On the other hand, all 
adrenalectomized mice were given B (25 µg/ml) in drinking fluid for 5 days and then, mice 
were separated into two groups: one group was deprived of B for 7 days [B (−)] while the 
other received B administration continuously (B surplus). Mice drank a significantly greater 
volume of fluid following ADX and the amount of corticosterone that was taken daily by 
mouse belongs to B surplus group was estimated to be 295 ± 20 g (Table 1). Twelve days 
after surgery, colchicine was injected intracerebroventricularly (i.c.v), mice were perfused 20 
hours later, and then brains were extracted for immunohistochemistry.  
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2.4. Brain perfusion and sectioning 
 
Mice were deeply anesthetized with chloral hydrate (i.p.) and were perfused transcardially 
through the ascending aorta with approximately 10 ml of 0.9% saline, followed by 10 ml of 
4% paraformaldehyde (PFA) containing 0.1 M phosphate buffer (PB), pH 7.4. After 
perfusion, brains were taken out immediately and immersed overnight in 4% 
paraformaldehyde at 4°C, followed by replacement with 30% sucrose containing 0.1 M PB 
until the tissue sank. The fixed brains were then embedded in Tissue Tek 
TM
 (Sakura Fine 
Technical Co. Ltd., Tokyo, Japan) at −40°C and stored at −80°C until use. Thirty μm coronal 
sections were cut by a cryostat (Microm HM505N, Heidelberg, Germany). The sections were 
kept in a cryoprotectant (30% ethylene glycol + 15% sucrose) solution and stored at 4°C until 
immunohistochemistry. 
 
2.5. Immunohistochemistry and X-gal staining 
 
2.5.1 Single Immunohistochemistry: Venus or EGFP 
 
For immunohistochemistry of Venus of CRF-Venus and CRF-Venusneo mouse or EGFP of 
CRF-EGFP mouse, free-floating sections were washed with phosphate-buffered saline (PBS). 
Then the sections were incubated for 18 h at 4°C with primary antibody rat anti-GFP 
(1:10,000; Nacalai Tesque, Kyoto, Japan) and 5% donkey serum as blocking solution. Then 
the sections were washed with PBS and incubated with secondary antibody anti-rat IgG 
conjugated with Alexa488 (donkey, 1:250; Invitrogen, Eugene, OR) for 2 h at room 
temperature. After washing with PBS, the sections were mounted on poly-L-lysine-coated 
glass slides using glycerin and observed both under fluorescent microscope (Leica DMR, 
Wetzler, Germany) and confocal microscope (Leica DM2500, Mannheim, Germany). 
 
2.5.2 Double Immunohistochemistry: Venus or EGFP with CRF, Copeptin, 
Vasopressin (AVP), Oxytocin (OXT), SRIF, TRH. 
 
The free floating sections were washed with phosphate-buffered saline (PBS) and incubated 
with 5% donkey serum as blocking solution and one or a combination of the following 
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primary antibodies: rat anti-GFP (1:10,000; Nacalai Tesque, Kyoto, Japan), rabbit anti-CRF 
(1:50,000; Shibasaki [37]), and goat anti-copeptin (1:15,000; Santa Cruz, Dallas, TX), rabbit 
anti-AVP (1: 5,000; [38]), rabbit anti-OXT (1:10,000; Chemicon, Billerica, MA), goat anti-
SRIF (1:500; Enzo Life Science, Farmingdale, NY), and sheep anti-TRH (1:100; [39]). The 
anti-GFP antibody was used to identify EGFP- and Venus-expression [40].The incubation 
period was 18 hours except for TRH (72 hours) 4°C. Then the sections were washed again 
with PBS and incubated with secondary antibodies for 2 hours at room temperature.  Anti-rat 
IgG conjugated with Alexa488 (donkey, 1:250; Invitrogen, Eugene, OR) was used as the 
secondary antibody for EGFP or Venus, anti-rabbit IgG conjugated with Alexa647 (donkey, 
1:500) for CRF, and anti-goat IgG conjugated with Alexa647 (donkey, 1:500) for copeptin, 
anti-rabbit IgG conjugated with Alexa647 (donkey, 1:500) for AVP and OXT, anti-goat IgG 
conjugated with Alexa647 (donkey, 1:500) for SRIF, and anti-sheep IgG conjugated with 
Alexa555 (donkey, 1:500) for TRH. The stained sections were captured by a confocal 
microscope (Leica DM2500, Mannheim, Germany).  
 
 
2.5.3 Double Immunohistochemistry: Venus or EGFP with CRF in the medial preoptic 
area, bed nucleus of stria terminalis, sensory motor cortex, central nucleus of 
amygdala, Barrington’s nucleus and inferior olivary nucleus. 
 
Colchicine was infused differently from aforementioned procedure. Small amount (4 g 
dissolved in 0.4 l saline) of colchicine was infused by bilateral injection under same 
stereotaxic control (coordinates from Bregma: anteroposterior, −0.2 mm; lateral, ±0.9 mm; 
dorsoventral from dura, −2.0 mm). Mice were perfused 72 h later, and then brains were 
collected. The immunohistochemistry procedure was same that described in earlier section 
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2.5.4 X-gal staining: 
 
For histological detection of -galactosidase, Z/CRF-iCre mice were fixed transcardially with 
4% paraformaldehyde in PBS. Coronal brain sections of 100 µm were cut by a vibratome 
(VT1000, Leica, Germany, Wetzlar). The brain sections were incubated at 37°C for 4 hours in 
PBS containing 5 mM potassium hexacyanoferrate (III), 5 mM potassium hexacyanoferrate 
(II), 2 mM MgCl2, and 1 mg/ml 5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-gal). 
Stained sections were observed under a microscope (MZ 16 FA, Leica) and captured by a 
digital camera (Pixera, Penguin 600CL-CU, Santa Clara, CA). 
 
2.6 Cell counting and densitometry  
 
Serial sections were taken from the entire rostrocaudal extent of the PVH, and five 
consecutive sections that contained the highest number of CRF and Venus neurons were used 
for counting and densitometry. Following immunohistochemical staining, cell images were 
captured by a confocal scanning microscope (Leica DM2500, Mannheim, Germany). Cell 
number was counted manually by using the Cell Counting Plug-in of Image J software 
(http://rsbweb.nih.gov/ij/). Densitometry was performed by Image J Basic Intensity 
Quantification Procedure; the background density was subtracted from the signals using a 
thresholding macro (BG_subtraction_from_ROI). The mean of the integrated density values 
(mean density × area), calculated for the 5 sections, was used for statistical analysis. 
 
2.7 Statistical analysis 
 
 Graph pad prism 5 software was used for statistical analysis, one way ANOVA followed by 
Tukey’s post-hoc test was carried out for comparison among three groups and paired t-test 
for comparison between two groups. Data are expressed as the means ± SEM. P < 0.05 was 










3.1. Distribution and comparison of Venus expression in the PVH between CRF-
Venus and CRF-Venus∆neo mouse: Venus with CRF expression was examined in the 
PVH of colchicine treated naive mouse by double immunohistochemistry (Figure 2). In CRF-
Venus mouse there was a considerable discrepancy between Venus and CRF expression 
whereas the number of Venus and CRF neurons were similar in the PVH of CRF-Venus∆neo 
mouse. In CRF-Venus mouse, some Venus cell was of lower intensity and some was of higher 
intensity. But in CRF-Venus∆neo mouse, all Venus cell was expressed with similar intensity. 
The number of Venus neurons in the PVH of CRF-Venus∆neo mouse was significantly 
greater than that of CRF-Venus mouse (Figure 2 and 3; Table 2). In the CRF-Venus mouse, a 
majority (57 ± 1%) of Venus neurons expressed CRF but approximately one third (38 ± 2%) 
CRF neurons expressed Venus. On the other hand, most of the Venus neurons (84 ± 5%) co-
express CRF and vice versa (84 ± 4%) in the CRF-Venus∆neo mouse (Figure 2 and 4; Table 
2).    
 
3.2. Distribution of more constitutive EGFP expression in the PVH of EGFP/CRF-
iCre mouse: Co-localization of EGFP with CRF was also examined in the PVH of 
colchicine treated naive EGFP/CRF-iCre mouse by double immunohistochemistry. In this 
mouse line, EGFP was expressed constitutively and in contrast to the CRF-Venus mouse, the 
number of EGFP was greater and similar to the number of CRF (Figure 5). On the other hand, 
most (85 ± 2%) of the EGFP neurons were co-expressed with CRF, and vice versa (81 ± 4%) 
in the PVH of this mouse line (Figure 6). 
 
3.3. Localization of Venus and EGFP-labeled neurons with vasopressin (AVP), 
oxytocin (OXT), somatostatin (SRIF) and thyrotropin-releasing hormone (TRH) in the 
PVH of CRF-Venus and EGFP/CRF-iCre mouse brain respectively: Double 
immunohistochemistry was carried out to examine whether Venus -expressing neurons co-
express with vasopressin (AVP), oxytocin (OXT), somatostatin (SRIF), or thyrotropin-
releasing hormone (TRH) in the PVH of naive colchicine-treated CRF-Venus mice. The 
Venus neurons did not express OXT, SRIF, or TRH. They were also devoid of AVP 
expression, with very few exceptions (Figure 7). The same experiment was carried out for 
EGFP/CRF-iCre mouse with identical procedure and EGFP neurons were also devoid of AVP 




expression, with very few exceptions and did not express OXT, SRIF, or TRH (Figure 8). 
 
 
3.4. Distribution of Venus-labeled neurons in the outside of PVH of CRF-Venus 
mouse brain: In colchicine-treated naive CRF-Venus mouse, distribution of Venus neurons 
was examined by single immunohistochemistry. Modest numbers of Venus neurons were 
observed in the medial preoptic area (Figure 9A; Table 3). The greatest density of stained cell 
was found just ventral to the anterior commissure and periventricular parts of the area. Both 
dorsal and ventral portions of the bed nucleus of the stria terminalis (BNST) had a moderate 
content of Venus cells throughout its rostrocaudal extent but the highest density was 
visualized at the lateral part of the area (Figure 9B; Table 3). A considerable number of Venus 
cells were also found in the piriform cortex (Figure 9C; Table 3) and scattered cells evenly 
distributed throughout the cerebral cortex (Figure 9D; Table 3). The vast majorities of cortical 
cells were distributed within layers II and III, bipolar in size and were oriented perpendicular 
to the surface of the cortex.  Besides the central amygdaloid nucleus (CeA), which contained 
numerous Venus cells (Figure 9E; Table 3), Venus cells were also seen both in the medial and 
lateral amygdaloid nucleus. A modest content of Venus cells were also expressed in the 
laterodorsal tegmental nucleus (Figure 9F; Table 3) and Barrington’s nucleus (Figure 9G; 
Table 3). In inferior olivary nucleus (Figure 9H; Table 3), a rich content of fibers and cells 
were found. Modest number of Venus-expressing neurons and fibres were also present in 
olfactory tubercle (Figure 10A; Table 3), and small number in the median raphe nucleus 
(Figure 10G; Table 3), lateral parabrachial nucleus (Figure 10I; Table 3) .Scattered cells were 
also found in lateral septum, accumbens nucleus, lateral hypothalamic area, periaqueductal 
gray, peduncular pontine tegmental nucleus, and nucleus of the solitary tract (Figure 10B, C, 
D, F, H and J respectively ; Table 3). Venus-expressing nerve endings were also confined in 
the external layer and very scantly distributed in the internal layer of the median eminence 
(Figure 10E). 
 
3.5. Distribution of Venus-labeled neurons in the outside of PVH of CRF-Venus∆neo 
mouse brain: In colchicine-treated naive CRF-Venus∆neo mouse, distribution of Venus 
neurons was examined by single immunohistochemistry. Venus neurons were distributed in 
all brain regions that described for CRF-Venus mouse (Figure 11and 12; Table 3) and the 
expression pattern was also similar except median eminence. Venus-expressing nerve endings 
were restricted in the external layer of median eminence but the density was greater than that 




of CRF-Venus mouse. 
 
 
3.6. Distribution ofgalactosidase-labeled neurons in the Z/CRF-iCre mouse brain: 
In naive Z/CRF-iCre mouse -galactosidase neurons examined by X-gal staining and the 
distribution pattern was also similar to Venus expression of CRF-Venus mouse (Figure 13). 
 
 
3.7. Distribution of EGFP-labeled neurons in the outside of PVH of EGFP/CRF-iCre 
mouse brain: In colchicine-treated naive EGFP/CRF-iCre mouse brain, distribution of 
EGFP was examined by identical procedure. EGFP neurons were observed in brain regions 
including the medial preoptic area, dorsal and ventral portions of the bed nucleus of the stria 
terminalis, cerebral cortex, central nucleus of the amygdala, piriform cortex, laterodorsal 
tegmental nucleus,  Barrington’s nucleus, inferior olivary nucleus (Figure 14 ; Table 3). 
EGFP-expressing neurons were also present in olfactory tubercle, lateral septum, accumbens 
nucleus, lateral hypothalamic area, periaqueductal gray, median raphe nucleus, peduncular 
pontine tegmental nucleus, lateral parabrachial nucleus, and nucleus of the solitary tract 
(Figure 15; Table 3). EGFP neurons were expressed more constitutively than Venus neurons 
in CRF-Venus mouse brain and the major discrepancy was observed in olfactory tubercle, 
accumbens nucleus and in piriform cortex where number of EGFP cell was greater than 
number of Venus neuron of CRF-Venus mouse (Table 3).  EGFP-expressing nerve endings 
were also concentrated in the external layer of the median eminence but more prominent than 
Venus nerve ending of CRF-Venus mouse (Figure 15E). 
 
3.8. Co-localization of Venus-labeled neurons with CRF in the medial preoptic area, 
bed nucleus of stria terminalis (BNST), sensory motor cortex, central nucleus of 
amygdala, Barrington’s nucleus and inferior olivary nucleus of CRF-Venus mouse 
brain: Double immunohistochemistry was carried out to examine the co-localization in the 
colchicine treated naive mouse. Venus neurons were clearly stained in all area but only dense 
fibers and small number of CRF neurons were visualized in most of the area. In the medial 
preoptic area, a considerable number of CRF neurons were found although the number was 
smaller than Venus neurons but most of them (approximately 80%) were expressed Venus 
(Figure 16, A row). A rich content of CRF fibers and small number of CRF neurons were 




visualized in the BNST and most of them (approximately 75%) expressed Venus (Figure 16, 
B row). In Sensory motor cortex, both CRF and Venus cells were clearly stained and most of 
the Venus cells expressed CRF although some cells were either Venus or CRF (Figure 16, C 
row). Central nucleus of amygdala had a dense content of CRF fiber and very few well-
structured CRF neuron and most of them were colocalized with Venus (Figure 17, A row). In 
Barington’s nucleus, both types of cells were clearly stained and majority of Venus cell 
(approximately 70%) expressed CRF and vice versa (Figure 17, B row). The distributed area 
of densely CRF fibers was exactly same of the area of well stained Venus neurons in inferior 
olivary nucleus. Some CRF neurons also recognized and they were colocalized with CRF 
neurons (Figure 17, C row). 
 
3.9. Co-localization of EGFP-labeled neurons with CRF in the medial preoptic area, 
bed nucleus of stria terminalis (BNST), sensory motor cortex, central nucleus of 
amygdala, Barrington’s nucleus and inferior olivary nucleus of EGFP/CRF-iCre 
mouse brain: Double immunohistochemistry was carried out to examine the co-localization 
with identical manner that used for CRF-Venus mouse and the colocalization pattern was 
almost similar except Barrington’s nucleus (Figure 18 and 19). In Barrington’s nucleus the 
number of EGFP was greater than CRF number and prominently expressed than Venus 
neurons of CRF-Venus mouse. In this mouse line, more than 90% CRF colocalized with 
EGFP in contrast approximately 70% EGFP neuron was colocalized with CRF. 
 
3.10. Distribution and glucocorticoid dependent expression of Venus neurons in the 
PVH of CRF-Venus mouse: Distribution and glucocorticoid dependent Venus expression 
with CRF neuron was examined in the PVH of CRF-Venus mouse by double 
immunohistochemistry (Figure 2). In sham operated or control CRF-Venus mouse there was a 
considerable discrepancy between Venus and CRF expression (Figure 20, control; Table 4). 
The number of CRF neurons increased significantly after B deprivation, but there was no 
significant increase in the number of Venus neurons [Figure 20 and 21, B (−); Table 4]. In 
mice which were given a high dose of B continuously, the numbers of Venus- and CRF 
neurons decreased markedly (Figure 20 and 21, B surplus; Table 4). In addition, 
immunofluorescent intensity of Venus and CRF, as was quantified by densitometry, increased 
after B deprivation by 54 ± 16% (Figure 22) and 94 ± 31% (Figure 23), respectively. The 
immunofluorescent intensity of Venus and that of CRF also decreased by 54 ± 7% (Figure 22) 
and 93 ± 3% (Figure 23) respectively after giving excess amount of B continuously. 




In the control (sham-operated) mouse, a majority (approximately 60%) of Venus neurons 
expressed CRF. On the other hand, only one third (approximately 33%) of CRF neurons 
expressed Venus (Figure 20 and 24, control; Table 4); thus, there was a considerable 
discordance between Venus- and CRF expression. For the purpose of activating CRF 
promoter, a group of mice was deprived of B for one week. Most of the Venus cells 
(approximately 80%) became expressing of CRF following B deprivation [Figure 20 and 24, 
B (−); Table 4]. In mice which were given a high dose of B continuously, the colocalization 
of Venus- and CRF neurons decreased markedly [(approximately 20% ) Figure 20 and 24, B 
surplus; Table 4].  
 
3.11. Expression of copeptin in the Venus cells following B deprivation in the PVH of 
CRF-Venus mouse: Distributions of Venus- and copeptin-expressing neurons were 
examined by double immunohistochemistry in the PVH of the CRF-Venus mouse (Figure 25). 
There was no significant change in the number of Venus neurons after B deprivation but 
markedly decreased in the mice which were given high dose of B continuously. In sham 
operated and B surplus group animals, the number of copeptin was similar but the number 
increased significantly after B deprivation (Figure 25 and 26; Table 5).  Very few Venus cells 
co-expressed copeptin in sham-operated animals (Figure 25 and 27, control; Table 5). One 
week following B deprivation, however, approximately half of the Venus cells expressed 
copeptin [Figure 25 and 27, B (−); Table 5]. In animals which were given a high dose of B, 
only a very few Venus cells expressed copeptin (Figure 25 and 27, B surplus; Table 5). By 
close observation of the copeptin expression, a majority of the Venus/copeptin dual 
expressing neurons was of lower intensity [arrows, Figure 25, B (−), insets]. In contrast, high-
intensity copeptin neurons predominated among those without Venus expression 















4.1. Comparative distribution of Venus expression in the PVH of CRF-Venus and 
CRF-Venus∆neo mouse brain. 
 
In the PVH of CRF-Venus mouse the number of Venus neurons was much smaller than CRF 
neuron and the intensity of Venus cell was variable that means some cell was of lower 
intensity and some cell was of higher intensity. A majority of Venus-expressing neurons 
expressed CRF in the physiological GC state, but a considerable number of neurons 
expressed only Venus or CRF. In this mouse line PGK–Neo cassette (a hybrid consisting of 
the phosphoglycerate kinase I promoter driving the neomycin phosphotransferase gene which 
was flanked by Flp recognition target (frt) sites) was inserted as a positive selection marker 
for homologous recombination in embryonic stem cells. On the other hand, in CRF-
Venus∆neo mouse (PGK–Neo was deleted by breeding CRF-Venus mouse with Actb-Flp 
knock-in mouse) Venus cell was expressed with similar intensity and the number was similar 
to the number of CRF neuron in the PVH, and most of the Venus neurons expressed CRF and 
vice versa. It has been reported that marker genes (PGK-Neo) can interfere the transcription 
and splicing of the target and neighboring gene, thereby introducing ambiguities in genotype 
–phenotype relationship but the mechanism is not yet clearly understood [41-43]. A final and 
very clear example of the effects of the PGKneo cassette is provided by the work of Fiering 
et al. (1995) who designed a targeted deletion of the 5΄ DNase hypersensitive site 2 (5΄ HS2) 
of the locus control region (LCR) of the -globin locus. They showed that the insertion of 
PGK–Neo abrogates the expression of multiple globin genes downstream from the cassette. 
Deletion of the selectable marker cassette results in restoration of LCR activity [44] . Pham et 
al. (1996) also reported that insertion of PGK–Neo into the murine granzyme B gene 
abrogates the expression of several granzyme genes within the granzyme B gene cluster [42]. 
N.Tamamaki et al. (2003) also evaluated the expression of GFP in GAD67-GFP mice and 
GAD67-GFPneo mice and they showed that in latter mice GFP intensity was much denser 
than that of earlier one [45]. However, the exact reason in this regard is not clear at this 
moment and further detail study is required to elucidate it. 
 
 





4.2. Distribution ofgalactosidase-labeled neurons in the Z/CRF-iCre brain and 
more constitutive EGFP expression in the PVH of EGFP/CRF-iCre mouse brain. 
 
The brain distribution of -galactosidase-expressing cells in the Z/CRF-iCre mouse 
brain and EGFP-expressing cells in the PVH of EGFP/CRF-iCre was similar to that of CRF 
neurons reported in previous literature [4, 27, 29, 46], indicating that the iCre-mediated 
recombination took place in a CRF-promoter dependent manner. It is noticeable that most 
EGFP neurons expressed CRF in the PVH of EGFP/CRF-iCre. The more constitutive EGFP 
expression, compared to the Venus expression, could be explained by the constitutive activity 
of CAG promoter, flanking the CAT-EGFP sequence of the reporter mouse [34]. Recently, 
Wamsteeker Cusulin and colleagues reported a mouse, in which TdTomato is driven by CAG 
promoter, for visualizing CRF neurons [28]. Both their driver mouse (Crh-IRES-Cre) and 
ours (CRF-iCre) are generated by the knock-in strategy, so the chromosomal locus, where the 
targeting DNA constructs were inserted, is identical, but the cell specific gene expression may 
also be dependent on the sequences of targeting vectors as well as the properties of reporters. 
Therefore, a precise comparison would be desirable as regards the distribution of TdTomato- 
and EGFP-expressing neurons, within as well as outside the PVH.  
 
4.3. Localization of Venus and EGFP-labeled neurons with vasopressin (AVP), 
oxytocin (OXT), somatostatin (SRIF) and thyrotropin-releasing hormone (TRH) in the 
PVH of CRF-Venus and EGFP/CRF-iCre mouse brain respectively. 
 
The Venus or EGFP cells were devoid of SRIF, TRH and almost devoid of AVP confirming 
the selectivity of Venus or EGFP expression in CRF neurons. The Venus/EGFP-expressing 
neurons did not express OXT, either. A small population of OXT neurons was reported to co-
localize with CRF in the rat, but it may not be in conflict with the present results; the 
OXT/CRF co-expressing neurons are most likely magnocellular neurons [47] , whereas Venus  









4.4. Distribution of Venus/EGFP neuron in the outside of PVH of CRF-Venus, CRF-
Venus∆neo, and EGFP/CRF-iCre mouse brain. 
 
CRF-Venus and CRF-Venus ∆neo mouse was generated to visualize CRF neurons with Venus 
fluorescence. In both mouse lines, the Venus-expressing cells were present in brain regions 
including olfactory tubercle, lateral septum, accumbens nucleus,  medial preoptic area, dorsal 
and ventral portions of the bed nucleus of the stria terminalis, cerebral cortex, central nucleus 
of the amygdala, piriform cortex, lateral hypothalamic area, periaqueductal gray, median 
raphe nucleus, peduncular pontine tegmental nucleus, laterodorsal tegmental nucleus,  
Barrington’s nucleus, lateral parabrachial nucleus, nucleus of the solitary tract, and  inferior 
olivary nucleus that was highly consistent with the distribution of CRF neurons, reported 
previously in mice [29, 46] and rats [4, 5, 27]. In the EGFP/CRF-iCre mouse EGFP 
expressed more constitutively in most of the aforementioned area could be explained by its 
expression under a strong promoter. But the most contrasting area was olfactory tubercle, 
accumbens nucleus, piriform cortex, central nucleus of amygdala and inferior olivary nucleus 
where EGFP number was greater than Venus number of CRF-Venus mouse and also 
inconsistent with CRF number according to previous studies [4, 29]. The reason is not clear 
at this moment whether it was because of ectopic expression or different expression pattern 
between at embryonic stage or adult stage of mouse. To elucidate it further detail study is 
required on expression and distribution pattern of mouse CRF and Venus/EGFP in those areas 
both at embryonic and adult stage in all mouse lines. It had been reported that in the median 
eminence CRF- immunoreactive nerve fibers are localized in large numbers in the median to 
paramedian portions of the external layer, extending perpendicularly from the internal layer 
to the capillary loops of the portal vessels. A small number of fine CRF-immunoreactive 
nerve fibers run tangentially in the internal layer [18, 19, 48]. Venus/EGFP nerve endings 
were also localized similarly in the median eminence.  
 
4.5. Co-localization of Venus and EGFP-labeled neurons with CRF in the medial 
preoptic area, bed nucleus of stria terminalis (BNST), sensory motor cortex, central 
nucleus of amygdala, Barrington’s nucleus and inferior olivary nucleus in the 
colchicine treated naive CRF-Venus and EGFP/CRF-iCre mouse brain. 
 
Double immunohistochemistry was carried out to examine the co-localization of Venus/EGFP 
with CRF in the mentioning area but only Venus/EGFP neurons were clearly stained in all 




area. In contrast, only dense fibers and small number of CRF neurons was visualized in most 
of the area even after small dose and long lasting administration of colchicine. However, 
these results also demonstrated the necessity to develop studied mouse lines to study CRF 
neuron in these areas. Double in situ hybridization or dual in situ and immunohistochemistry 
are required to explore the colocalization in the mentioning area. 
 
4.6. Glucocorticoid dependent Venus expression in the PVH of CRF-Venus mouse. 
 
The co-localization of Venus with CRF was examined more precisely in the PVH of the 
CRF-Venus mouse. At physiological GC state, a majority of Venus-expressing neurons 
expressed CRF. However, a considerable number of neurons expressed only Venus or CRF 
because CRF promoter activity may be partly suppressed by B under the physiological 
condition [49] .So we examined the effect of B deprivation to see if it may enhance co-
localization of Venus with CRF.  
 
One week following B deprivation, the number of Venus cells co-expressing CRF increased 
significantly, and most Venus neurons became expressing of CRF. This raises the possibility 
that the Venus-expressing cells, in which CRF expression could not be verified in the 
physiological GC state, may actually be the ‘CRF neurons’. In contrast, a majority of CRF 
neurons did not co-express Venus even after B deprivation, and the reason is not clear at this 
moment. On the other hand, the immunofluorescent intensity of Venus and CRF increased 
significantly following B deprivation and was suppressed by excess B administration. Thus, 
Venus neurons partially recapitulated the GC-dependent responses of PVH-CRF neurons [1, 
24, 50].  
 
4.7. Expression of copeptin in the Venus cells following B deprivation in the PVH of 
CRF-Venus mouse. 
       
  In a physiological GC state, Venus neurons were almost devoid of copeptin. In contrast, a 
major proportion of Venus cells expressed copeptin after B deprivation, which was reversed 
by B administration. It is well known that CRF neurons are capable of producing AVP in the 
PVH, and both CRF and AVP are regarded secretagogues for adrenocorticotropin in the 
pituitary [1]. In rats, CRF colocalization with AVP in parvocellular neuroendocrine cells 
(PNCs) has only been reported when glucocorticoids are removed [51]or after repeated stress 




[52]. However, AVP gene expression in CRF neurons is mostly suppressed in the 
physiological GC state and becomes eminent by GC deprivation [24, 53, 54]. In our study, 
approximately fifty percent Venus neuron express AVP after glucocorticoid deprivation. 




However, the genomic construct of CRF-Venus mouse was designed so that Venus 
expression was driven by the CRF promoter. The study demonstrated that Venus usually 
expressed where CRF neurons known to express and its expression in the PVH was strictly 
depends on the glucocorticoid state of the animal. This may be an advantage for monitoring 
dynamic changes in CRF neurons and CRF networks in different glucocorticoid states, 
including elevated glucocorticoid conditions (e.g., Cushing syndrome) and glucocorticoid 
deficiency (e.g., Addison’s disease). In CRF- Venus∆neo mouse, Venus was also inserted 
under CRF promoter and it was expressed more consistently and pattern of expression was 
similar to CRF in the PVH but Glucocorticoid dependent Venus expression in this mouse line 
not yet to be studied.  On the other hand, EGFP/CRF-iCre and the mouse reported by 
Wamsteeker Cusulin and colleagues may have the advantage of the ability to more 
consistently label CRF neurons because EGFP and TdTomato both were inserted under 
strong promoter and expressed consistently. So the characterizations of the reporter mouse 
lines confirm faithful recapitulation of central CRF expression and preserved functionality in 
the regions assessed. So it has been suggested that the integrity and tractability of these 
















Table 1: Calculation of amount of drinking water taken by different group of CRF-Venus mouse 
daily. 
     
  Volume of water taken/day  Amount of B (g) taken/day 
     
Control  7.3 ± 0.8  ----- 
     
B (−)  11.79 ± 0.77 **  ---------- 
     
B surplus  11.82 ± 0.79 **  295.5 ± 19.75 
     
Amount of drinking water was calculated daily throughout the study. n = 5 for control, n = 4 for 



















































Table 2: Comparison of number of Venus-, CRF-, or Venus/CRF-expressing neurons in 
the PVH between CRF-Venus and CRF-Venus∆neo mouse. 
     
 
No. of Venus 
neurons 
No. of CRF 
neurons 
% of Venus 
neurons 
expressing CRF 




     
CRF-Venus 49 ± 4 81 ± 3 57 ± 1 38 ± 2 
     
CRF-Venus 
∆neo 
92 ± 4 ** 89 ± 4 84 ± 5 * 84 ± 4 ** 
     
The mean number of Venus-, CRF neurons in unilateral PVH was calculated using 2 
medial sections per animal (n = 3). The mean percentage of Venus-expressing neurons 
which co-express CRF and that of CRF-expressing neurons which co-express Venus were 
also calculated. *, P < 0.05, **, P < 0.01 vs. CRF-Venus; Paired t-test.                                                                                                                                            




Table 3: Comparative distribution of Venus and EGFP cell number in the outside of PVH of 
studied mouse lines. 
    
Brain Region CRF-Venus CRF-Venus∆neo EGFP/CRF-iCre 
    
Olfactory tubercle ** ** **** 
Lateral septum * * * 
Accumbens nucleus * * **** 
Medial preoptic area *** *** **** 
Bed nucleus of stria terminalis ** ** *** 
Cortex * * * 
Piriform cortex *** *** **** 
Central nucleus of amygdala *** *** **** 
Lateral hypothalamus * * * 
Periaqueductal gray * * ** 
Median Raphe nucleus * * * 
Peduncular pontine tegmental nucleus * ** ** 
Later dorsal tegmental nucleus *** *** *** 
Lateral parabrachial nucleus * * * 
Barrington’s nucleus ** ** ** 
Inferior olive **** **** **** 
Nucleus of the solitary tract * * * 
*, Scattered cell or Mild number (1-20 cells/section); **, Modest number (21-50 










































Table 4: The number of Venus-, CRF-, or Venus/CRF-expressing neurons in the PVH of CRF-
Venus mouse 





















          
control 50 ± 1 
 
93 ± 4 
 
29 ± 2 
 
59 ± 5 
 
32 ± 1 
          

















          














          
The mean number of Venus-, CRF-, or Venus/CRF-expressing neurons in unilateral PVH was 
calculated using 5 sections per animal (n = 4). The mean percentage of Venus-expressing 
neurons which co-express CRF and that of CRF-expressing neurons which co-express Venus 
were also calculated.                                                                                                                                                                                                               
*, P < 0.05, **, P < 0.01 vs. control; ✝, P < 0.05, ✝✝, P < 0.01 vs. B (−); ANOVA followed by 
Tukey’s post- hoc test. 





Table 5: The number of Venus-, copeptin-, or Venus/copeptin-expressing neurons in the PVH 
of CRF-Venus mouse. 
          
 No. of 
Venus 
neurons 
 No. of 
copeptin 
neurons 
 No. of 
Venus/copeptin 
neurons 










          
Control 49 ± 7  83 ± 3  1 ± 1  1 ± 1  1 ± 1 
          
B (−) 57 ± 10  143 ± 19
*
  27 ± 7
**
  46 ± 8
**
  18 ± 3
**
 
          
B surplus 29 ± 3✝  85 ± 8✝  2 ± 2✝✝  6 ± 3✝✝  2 ± 1✝✝ 
          
The mean number of Venus-, Copeptin-, or Venus/copeptin-expressing neurons in unilateral 
PVH was calculated using 5 sections per animal (n = 4). The mean percentage of Venus-
expressing neurons which co-express copeptin and that of copeptin-expressing neurons which 
co-express Venus were also calculated.                                                                                                            
*, P < 0.05, **, P < 0.01 vs. control; ✝, P < 0.05, ✝✝, P < 0.01 vs. B (−); ANOVA followed 





























Figure 1: A strategy for knocking Venus (Vns) - or iCre gene into the mouse crf genomic 
locus is presented schematically. A, B, C, D, and E represent the mouse crf genome, the 
targeting vector, the Venus-targeted allele, Venus-targeted allele without neo and the iCre-
targeted allele, respectively. By homologous recombination in the ES cells, the Venus (C) or 
iCre (E), together with the pgk-neomycin resistant cassette (Neo), was inserted at the 
translation initiation site of the crf gene. The exons of the crf gene are represented by gray-
colored boxes, while Venus and iCre sequences, frt-flanked Neo, and diphtheria toxin (DT) 













Figure 2: Photomicrographs representing distribution of Venus-expressing neurons (green) 
and CRF-expressing neurons (red) in the PVH of CRF-Venus and CRF-Venus∆neo mouse. 
Insets: circumscribed areas are shown in a higher magnification at the right lower angle of 
each photomicrograph. Arrows indicate the neurons which express both Venus and CRF. III, 




















Figure 3: Comparison the number of Venus and CRF neurons per unilateral PVH between 
CRF-Venus and CRF-Venus∆neo mouse. Values are mean ± SEM. **, P < 0.01; Paired t-test.  




























































Figure 4: Percentage of Venus cell that express CRF and vice versa in the PVH of CRF-
Venus and CRF-Venusneo mouse. Values are mean ± SEM. *, P < 0.05, **, P < 0.01; Paired 




















% of Venus express
CRF




























Figure 5: Photomicrographs representing distribution of EGFP-expressing neurons (green) 
and CRF-expressing neurons (red) in the PVH of EGFP/CRF-iCre naive colchicine treated 
mouse. Inset: circumscribed area is shown in a higher magnification at the right lower angle 
of photomicrograph. Arrows indicate the neurons which express both EGFP and CRF. III, 






























Figure 6: Percentage of EGFP cells that express CRF and vice versa in the PVH of 























































Figure 7: Double immunohistochemistry was carried out to examine whether the Venus-
expressing neurons co-express vasopressin (AVP) (A), oxytocin (OXT) (B), somatostatin 
(SRIF) (C), or thyrotropin-releasing hormone (TRH) (D) in the PVH of naive colchicine-
treated CRF-Venus mice; representative dual confocal photomicrographs are shown. The 
Venus neurons did not express OXT, SRIF, or TRH. They were also devoid of AVP 
expression, with very few exceptions. Venus is colored green, AVP, OXT, SRIF, and TRH 

























Figure 8: Double immunohistochemistry was carried out to examine whether the EGFP-
expressing neurons co-express vasopressin (AVP) (A), oxytocin (OXT) (B), somatostatin 
(SRIF) (C), or thyrotropin-releasing hormone (TRH) (D) in the PVH of naive colchicine-
treated EGFP/CRF-iCre mice; representative dual confocal photomicrographs are shown. 
The EGFP neurons did not express OXT, SRIF, or TRH. They were also devoid of AVP 
expression, with very few exceptions. EGFP is colored green, AVP, OXT, SRIF, and TRH 

















Figure 9: Representative photomicrographs of Venus-expressing neurons in the outside of 
PVH of colchicine treated naive CRF-Venus brain are shown in A-H. Distribution of Venus 
neurons was examined by single immunohistochemistry.  Medial preoptic area (A), dorsal 
bed nucleus of stria terminalis (B), piriform cortex (C), sensory motor cortex (D), central 
nucleus of the amygdala (E), laterodorsal tegmental nucleus (F), Barrington’s nucleus (G), 
and inferior olivary nucleus (H). LV, lateral ventricle, AC, anterior commissure, IV, fourth 
ventricle. Scale bar = 250 m. 
  



















Figure 10: Representative photomicrographs of Venus-expressing neurons in the outside of 
PVH of colchicine treated naive CRF-Venus brain are shown in A-J. Distribution of Venus 
neurons was examined by single immunohistochemistry.  Olfactory tubercle (A), lateral 
septum (B), accumbens nucleus (C), lateral hypothalamus (D), median eminence (E), 
periaqueductal gray (F), median raphe nucleus (G), peduncular  pontine tegmental nucleus 
(H), lateral parabrachial nucleus (I), and nucleus of the solitary tract (J). LV, lateral ventricle, 












Figure 11: Representative photomicrographs of Venus-expressing neurons in the outside of 
PVH of colchicine treated naive CRF-Venus∆neo mouse brain are shown in A-H. 
Distribution of Venus neurons was examined by single immunohistochemistry. Medial 
preoptic area (A), bed nucleus of stria terminalis (B), piriform cortex (C), sensory motor 
cortex (D), central nucleus of the amygdala (E), laterodorsal tegmental nucleus (F), 
Barrington’s nucleus (G), and inferior olivary nucleus (H). LV, lateral ventricle, AC, anterior 












Figure 12: Representative photomicrographs of Venus-expressing neurons in the outside of 
PVH of colchicine treated naive CRF-Venus∆neo brain are shown in A-J. Distribution of 
Venus neurons was examined by single immunohistochemistry.  Olfactory tubercle (A), 
lateral septum (B), accumbens nucleus (C), lateral hypothalamus (D), median eminence (E), 
periaqueductal gray (F), median raphe nucleus (G), peduncular  pontine tegmental nucleus 
(H), lateral parabrachial nucleus (I), and nucleus of the solitary tract (J). LV, lateral ventricle, 
Aq, aqueduct, III, third ventricle. Scale bar = 250 m. 
 
 










Figure 13: Representative photomicrographs of -galactosidase-expressing neurons in the 
Z/CRF-iCre brain in (A-F).-galactosidase neurons examined by X-gal staining. Bed nucleus 
of stria terminalis (A), piriform cortex (B), paraventricular nucleus (C), central nucleus of the 
amygdala (D), Barrington’s nucleus (E), and inferior olivary nucleus (F). AC, anterior 



















Figure 14: Representative photomicrographs of EGFP-expressing neurons in the outside of 
PVH of colchicine treated naive EGFP/CRF-iCre brain are shown in A-H. Distribution of 
EGFP neurons was examined by single immunohistochemistry. Medial preoptic area (A), bed 
nucleus of stria terminalis (B), piriform cortex (C), sensory motor cortex (D), central nucleus 
of the amygdala (E), laterodorsal tegmental nucleus (F), Barrington’s nucleus (G), and 
inferior olivary nucleus (H). LV, lateral ventricle, AC, anterior commissure, IV, fourth 











Figure 15: Representative photomicrographs of EGFP-expressing neurons in the outside of 
PVH of colchicine treated naive EGFP/CRF-iCre brain are shown in A-J. Distribution of 
EGFP neurons was examined by single immunohistochemistry.  Olfactory tubercle (A), 
lateral septum (B), accumbens nucleus (C), lateral hypothalamus (D), median eminence (E), 
periaqueductal gray (F), median raphe nucleus (G), peduncular  pontine tegmental nucleus 
(H), lateral parabrachial nucleus (I), and nucleus of the solitary tract (J). LV, lateral ventricle, 













Figure 16: Photomicrographs representing distribution of Venus-expressing neurons 
(green), CRF-expressing neurons (red) and merged view in the medial preoptic area (A row), 
dorsal bed nucleus of stria terminalis (B row), and sensory motor cortex (C row) of colchicine 
treated naive CRF-Venus mouse. Enlarged: circumscribed areas are shown in a higher 
magnification at the right side of each photomicrograph. Arrows indicate the neurons which 














Figure 17: Photomicrographs representing distribution of Venus-expressing neurons 
(green), CRF-expressing neurons (red) and merged view in the central nucleus of amygdala 
(A row), Barrington’s nucleus (B row), and inferior olivary nucleus (C row) of colchicine 
treated naive CRF-Venus mouse. Enlarged: circumscribed areas are shown in a higher 
magnification at the right side of each photomicrograph. Arrows indicate the neurons which 
















Figure 18: Photomicrographs representing distribution of EGFP-expressing neurons (green), 
CRF-expressing neurons (red) and merged view in the medial preoptic area (A row), dorsal 
bed nucleus of stria terminalis (B row), and sensory motor cortex (C row) of colchicine 
treated naive EGFP/CRF-iCre mouse. Enlarged: circumscribed areas are shown in a higher 
magnification at the right side of each photomicrograph. Arrows indicate the neurons which 
















Figure 19: Photomicrographs representing distribution of EGFP-expressing neurons (green), 
CRF-expressing neurons (red) and merged view in the central nucleus of amygdala (A row), 
Barrington’s nucleus (B row), and inferior olivary nucleus (C row) of colchicine treated naive 
EGFP/CRF-iCre mouse. Enlarged: circumscribed areas are shown in a higher magnification 
at the right side of each photomicrograph. Arrows indicate the neurons which express both 
Venus and CRF. Scale bars = 100 m (25m for insets). 









Figure 20: Photomicrographs representing distribution of Venus-expressing neurons (green) 
and CRF-expressing neurons (red) in the PVH of different group of CRF-Venus mouse. 
Control, sham-operated mouse; B (−), B-deprived mouse; B surplus, mouse given excess B 
continuously after ADX. Insets: circumscribed areas are shown in a higher magnification at 
the right lower angle of each photomicrograph. Arrows indicate the neurons which express 






















Figure 21: Number of Venus and CRF neurons per unilateral PVH in the different group of 
CRF-Venus mouse. Control, sham-operated mouse; B (−), B-deprived mouse; B surplus, 
mouse given excess B continuously after ADX. Values are mean ± SEM.  *, P < 0.05, **,     
P < 0.01 vs. control; †, P < 0.05, ††, P < 0.01 vs. B (−); ANOVA followed by Tukey’s post-
























































Figure 22: Intensity of Venus neurons per unilateral PVH in the different group of CRF-
Venus mouse. Control, sham-operated mouse; B (−), B-deprived mouse; B surplus, mouse 
given excess B continuously after ADX. The mean of the integrated density values (mean 
density × area) for control normalized into 100 and compare with the values for B (−) and B 

















































Figure 23: Intensity of CRF neurons per unilateral PVH in the different group of CRF-
Venus mouse. Control, sham-operated mouse; B (−), B-deprived mouse; B surplus, mouse 
given surplus B continuously after ADX. The mean of the integrated density values (mean 
density × area) for control normalized into 100 and compare with the values for B (−) and B 

















































Figure 24: Percentage of Venus cell that express CRF and vice versa in the PVH of 
different group of CRF-Venus mouse. Control, sham-operated mouse; B (−), B-deprived 
mouse; B surplus, mouse given excess B continuously after ADX. *, P < 0.05, **, P < 0.01 
vs. control; †, P < 0.05, ††, P < 0.01 vs. B (−); ANOVA followed by Tukey’s post-hoc test. 
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Figure 25: Comparative distribution of Venus-expressing neurons to that of copeptin-
expressing neurons in the PVH of the different group of CRF-Venus mouse. Control, sham-
operated mouse; B (−), B-deprived mouse; B surplus, mouse given surplus B continuously 
after ADX. Insets: circumscribed areas are shown in a higher magnification at the right lower 
angle of each photomicrograph. In a majority of the Venus/copeptin expressing neurons, the 
copeptin expression was of lower intensity (arrows), but high-intensity copeptin neurons 
predominated among those without Venus expression (arrowheads) although low-intensity 
ones were also present (asterisk). III, the side facing the third ventricle. Scale bar = 100 m 




















Figure 26: Number of Venus and copeptin (Vasopressin) neurons per unilateral PVH in the 
different group of CRF-Venus mouse. Control, sham-operated mouse; B (−), B-deprived 
mouse; B surplus, mouse given surplus B continuously after ADX. Values are mean ± SEM. 
*, P < 0.05 vs. control; †, P < 0.05 vs. B (−); ANOVA followed by Tukey’s post-hoc test.       






















































Figure 27: Percentage of Venus cells that express copeptin and vice versa in the PVH of 
different group of CRF-Venus mouse. Control, sham-operated mouse; B (−), B-deprived 
mouse; B surplus, mouse given surplus B continuously after ADX. Values are mean ± SEM. 
**, P < 0.01 vs. control; ††, P < 0.01 vs. B (−); ANOVA followed by Tukey’s post-hoc test.     
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1.  In all mouse lines, Venus or EGFP was expressed in most brain regions which are 
known to express CRF. 
2. In the PVH of CRF-Venus mouse, colocalization ratio of Venus with CRF was 
related to the circulating glucocorticoid levels: this is probably because Venus is 
under the control of CRF promoter. 
3. In the PVH of CRF-Venus∆neo mouse, Venus was expressed prominently and the 
number was similar to the number of CRF neuron, and mostly Venus neuron 
expressed CRF and vice versa. 
4. In the PVH of EGFP/CRF-iCre mouse, most CRF neurons expressed EGFP, and vice 
versa, whether or not it underwent ADX: this is probably because EGFP is expressed 
under the CAG promoter. 
5. At physiological stage, the PVH-Venus or EGFP cells were devoid of SRIF, TRH, 
OXY and almost devoid of AVP confirming the selectivity of Venus or EGFP 
expression in CRF neurons. 
6. Majority of Venus neurons expressed copeptin (vasopressin) following B deprivation 
in the PVH of CRF-Venus mouse, which was not observed in mice either sham 
operated or given high dose of B continuously. This is recapitulating the 


















In this study a novel mouse line, CRF-Venus, is presented. The genomic construct of the 
mouse was designed so that the Venus expression is driven by CRF promoter. As was 
demonstrated in the present study, Venus expression in the PVH was strictly dependent upon 
the GC state of the animal. This may be an advantage in monitoring the dynamic changes in 
CRF neurons and CRF networks during different GC states, including high GC state and GC 
deficiency. CRF-Venusneo mouse also presented in which Venus expressed more 
constitutively, and Venus expression is also driven by CRF promoter but detail study is 
required to demonstrate this mouse line.  
 
On the other hand, EGFP/CRF-iCre and the mouse reported by Wamsteeker Cusulin and 
colleagues may have an advantage in labeling CRF neurons more constitutively. Therefore, 
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